«Hct116 Cells

Below is an extended Hct116 Cells patents listing. Click here to return to the Hct116 Cells main in depth entry.

Patents :
US Patent No.	Title
7173029	Fused heteroaryl derivatives
7226903	Interferon beta: remodeling and glycoconjugation of interferon beta
7229617	Methods and compositions for inducing apoptosis in cancer cells
7232822	Reverse-turn mimetics and method relating thereto
7241743	Sir2.alpha.-based therapeutic and prophylactic methods
7247734	3,4-diarylpyrazoles and their use in the therapy of cancer
7250430	Thiophene-and thiazolesulfonamides as antineoplastic agents
7250435	Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
7250488	Transcriptional activation inhibitory protein
7253204	Inhibitors of histone deacetylase
7253258	Proline rich acidic protein and uses thereof
7220410	Monoclonal antibodies to hepatocyte growth factor
7214660	Erythropoietin: remodeling and glycoconjugation of erythropoietin
7173115	Stra6 polypeptides
7176277	Conversion of apoptotic proteins
7179617	Factor IX: remolding and glycoconjugation of Factor IX
7179619	Methods and compositions for inhibiting herpesviral replication
7179912	Materials and methods to potentiate cancer treatment
7183320	Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents
7189840	Oncosuppressive gene
7196068	Method for treating cancer using p38/JTV-1 and method for screening pharmaceutical composition for treating cancer
7205326	Aniline derivatives, their manufacture and use as pharmaceutical agents
7214480	Methods and compositions for diagnosing and suppressing metastasis thereof
7265084	Glycopegylation methods and proteins/peptides produced by the methods
7276612	Hydroxamates as therapeutic agents
7354703	Securin is required for chromosomal stability in human cells
7358335	ARF-BP1 as mediator of p53-dependent and independent tumor suppression and uses thereof
7368476	Hydroxamates as therapeutic agents
7371527	Hypermethylation of GATA-4 and GATA-5 transcription factor genes in cancer
7388010	Quinoxalinone derivatives
7399613	Sialic acid nucleotide sugars
7407985	Compounds that abrogate DNA damage induced cell cycle G2 checkpoint and/or augment anti-cancer activity of DNA-damaging treatments
7415359	Methods and systems for the identification of components of mammalian biochemical networks as targets for therapeutic agents
7420089	Hydroxamates as therapeutic agents
7422862	Methods for identifying modulators of apoptosis
7344710	Combination bacteriolytic therapy for the treatment of tumors
7342114	Podophyllotoxin derivatives
7282595	Antitumor benzoylsulfonamides
7282608	Inhibitors of histone deacetylase
7288405	Devices and methods for pharmacokinetic-based cell culture system
7297511	Interferon alpha: remodeling and glycoconjugation of interferon alpha
7297779	Colon cancer metastasis inhibitor
7312237	Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases
7319036	Method for generating hypermutable organisms
7326687	CNGH0010 specific polynucleotides, polypeptides, antibodies, compositions, methods and uses
7329529	Ubiqutin proteases
7342093	Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
7425612	Genes and polypeptides relating to human colon cancers

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.